A chronological record of peer-reviewed Tesamorelin research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Tesamorelinworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: GHRH Receptor Agonism. Primary indications investigated: Visceral fat reduction, HIV lipodystrophy, Cognitive function (research).
Study measuring appetite hormones (leptin, ghrelin, PYY) and food intake patterns during tesamorelin administration.
Study of tesamorelin effects on liver fat content and fibrosis in HIV-positive patients with metabolic syndrome.
Detailed lipoprotein analysis examining tesamorelin effects on LDL, HDL, triglycerides, and apolipoprotein composition.
Study of tesamorelin effects on lipid profile, inflammatory markers, and vascular function in HIV patients.
Safety monitoring study assessing liver and kidney function tests during tesamorelin therapy in HIV patients.
Comprehensive neurocognitive testing battery examining tesamorelin effects on HIV-associated cognitive impairment.
Cellular study examining GHRH receptor expression in visceral adipose tissue from HIV-positive patients.
Longitudinal study of long-term tesamorelin administration (24+ weeks) assessing durability and reversal of lipodystrophy features.
Study examining tesamorelin effects on bone metabolism, P1NP, CTX, and bone mineral density in HIV-positive patients.
Metabolic study examining tesamorelin effects on growth hormone signaling, IGF-1 levels, and insulin sensitivity in HIV patients.
Open-label extension of REDUCE trials documenting continued efficacy and safety during prolonged tesamorelin administration.
Detailed body composition analysis using DEXA and CT imaging to assess tesamorelin effects on fat distribution and lean mass.
Mechanistic study of tesamorelin-stimulated GH secretion patterns and IGF-1 production in HIV-positive subjects.
Comprehensive safety review combining data from 600+ HIV-positive patients across multiple tesamorelin trials.
Pivotal RCT showing tesamorelin reduced visceral adipose tissue by 15.4% in HIV patients with lipodystrophy.
Second pivotal Phase 3 trial confirming tesamorelin visceral fat reduction with extended follow-up through 52 weeks.
Phase 3 RCT of tesamorelin 2mg daily versus placebo in HIV-positive patients with lipodystrophy measuring visceral adipose tissue by CT.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Tesamorelin is L5 (FDA Approved): fda-approved for at least one human indication. Treat each study as one data point, not a conclusion.
PeptideMark indexes 36 studies on Tesamorelin: 18 human studies, 8 animal studies, 3 in-vitro, and 7 reviews. The current evidence level is L5 — fda approved.
The earliest indexed peer-reviewed study on Tesamorelin in the PeptideMark library was published in 2006 (AIDS). Research activity has continued through 2016.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Tesamorelin has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.